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Purpose: In advanced gastric cancer, peritoneal dissemination is a life‐threatening 
mode of metastasis. Since the treatment options with conventional chemotherapy re-
main limited, any novel therapeutic strategy that could control such metastasis would 
improve the outcome of treatment. We recently developed a unique RNA interference 
therapeutic regimen (DFP‐10825) consisting of short hairpin RNA against thymi-
dylate synthase (TS shRNA) and cationic liposomes. The treatment with DFP‐10825 
has shown remarkable antitumor activity in peritoneally disseminated human ovarian 
cancer–bearing mice via intraperitoneal administration. In this study, we expanded 
DFP‐10825 to the treatment of peritoneally disseminated gastric cancer.
Methods: DFP‐10825 was administered intraperitoneally into mice with intraperi-
toneally implanted human gastric cancer cells (MKN45 or NCI‐N87). Antitumor 
activity and host survival benefits were monitored. Intraperitoneal distribution of 
fluorescence‐labeled DFP‐10825 was monitored in this MKN45 peritoneally dis-
seminated mouse model.
Results: Intraperitoneal injection of DFP‐10825 suppressed tumor growth in two 
peritoneally disseminated cancer models (MKN45 and NCI‐N87) and increased the 
survival time of the MKN45 model without severe side effects. Throughout the treat-
ment regimen, no significant body weight loss was associated with the administra-
tion of DFP‐10825. Interestingly, after intraperitoneal injection, fluorescence‐labeled 
DFP‐10825 retained for more than 72 hours in the peritoneal cavity and selectively 
accumulated in disseminated tumors.
Conclusions: Intraperitoneal injection of DFP‐10825 demonstrated effective anti-
tumor activity without systemic severe adverse effects via the selective delivery of 
RNAi molecules into disseminated tumors in the peritoneal cavity. Our current study 
indicates that DFP‐10825 could become an alternative option to improve the out-
comes of patients with peritoneally disseminated gastric cancer.
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1 |  INTRODUCTION
Gastric cancer is the fifth most common cancer around the 
world and is the third leading cause of cancer‐related death.1 
In advanced gastric cancers, peritoneal dissemination is the 
most life‐threatening development, because it frequently 
causes severe clinical symptoms such as malignant ascites 
and intestinal obstruction.2-4 For the treatment of peritoneally 
disseminated gastric cancer, cytoreductive surgery and sys-
temic chemotherapy are the standard option in clinical cases. 
Several reports have indicated, however, that systemic chemo-
therapy is ineffective for peritoneal dissemination, because 
the systemic anticancer agents cannot reach into the lesion 
in the peritoneal cavity where the disseminated tumors de-
velop.5 To conquer this problem, intraperitoneal chemother-
apy has recently been introduced as a novel strategy to treat 
peritoneally disseminated gastric cancer.6,7 Intraperitoneal 
chemotherapy is expected to directly expose disseminated 
tumors to treatment drugs, which would simplify the process 
of controlling drug concentration in the peritoneal cavity. In 
fact, several clinical studies have elucidated the advantages of 
intraperitoneal chemotherapy for gastric peritoneal dissem-
ination.8,9 Nevertheless, no effective treatment has yet im-
proved the survival rates of patients, because intraperitoneal 
anticancer agents tend to be rapidly removed from the perito-
neal cavity via the circulatory system, which prevents the ad-
ministration of a therapeutic concentration to the peritoneal 
cavity within a sufficient therapeutic window.10 Accordingly, 
a novel therapeutic approach that would control peritoneal 
dissemination in advanced gastric cancer is required to in-
crease the survival rates of patients.
We recently developed the DFP‐10825 formulation, which 
is a unique RNAi molecule consisting of shRNA against thy-
midylate synthase (TS) and a cationic liposome, which is 
intended for local administration11 and systemic injection.12 
Thymidylate synthase is well‐known as an important enzyme 
that is involved in the DNA synthesis/repair of cancer cells 
and tumor malignancy13-15; fluoropyrimidines are designed 
to primarily target TS,16 along with its derivatives.17 Systemic 
injection of DFP‐10825 improved the therapeutic efficacy 
of S‐1 orally administered in a colorectal cancer xenograft 
mouse model.18 S‐1 is an oral anticancer drug combined of 
1‐(2‐tetrahydrofuryl)‐5‐fluorouracil (tegafur), 5‐chloro‐2,4‐
dihydropyrimidine, and potassium oxonate in a molar ratio 
of 1:0.4:1, which is standard care for gastric cancer. An in-
jection of DFP‐10825 also improved the therapeutic effect of 
pemetrexed (PMX) intraperitoneally administered to a subcu-
taneous malignant mesothelioma xenograft mouse model.12 
In addition, intrapleural injection of DFP‐10825 increased 
the therapeutic effect of PMX peritoneally administered to a 
malignant pleural mesothelioma orthotropic xenograft mouse 
model via suppression of TS expression in implanted meso-
thelioma cells.11
To expand the therapeutic application of DFP‐10825, in 
this study, we demonstrated the antitumor activity of intraperi-
toneally delivered DFP‐10825 on a peritoneally disseminated 
gastric cancer mouse model. The model mice were treated 
with either DFP‐10825 or S‐1. As we expected, the treatment 
with oral S‐1 did not produce the antitumor effects on peri-
toneally disseminated tumors. In contrast, the intraperitoneal 
treatment with DFP‐10825 showed superior therapeutic ef-
fects without any systemic adverse events. The present study 
shows that intraperitoneal delivery of DFP‐10825 could be 
a feasible therapeutic approach to treat peritoneally dissemi-
nated gastric cancer.
2 |  MATERIALS AND METHODS
2.1 | Materials
Thymidylate synthase shRNA for clinical use produced 
by a scaled‐up rate of synthesis was obtained from Nitto‐
Denko Avecia (Milford). The TS shRNA sequence was 
5′‐GUA ACA CCA UCG AUC AUG AUA GUG CUC 
CUG GUU GUC AUG AUC GAU GGU GUU ACU 
U‐3′. Fluorescently labeled Alexa750 TS shRNA was pur-
chased from GeneDesign. Dioleoyl phosphatidylethanola-
mine (DOPE) and dioleoyl phosphatidylcholine (DOPC) 
were kindly provided by NOF. A cationic lipid, O,O′‐
ditetradecanoyl‐N‐(α‐trimethyl ammonio acetyl) dietha-
nolamine chloride (DC‐6‐14), was purchased from Sogo 
Pharmaceutical. The anticancer agent S‐1 was obtained from 
Taiho Pharmaceutical. 1,1′‐Dioctadecyl‐3,3,3′,3′‐tetrameth-
ylindotricarbocyanine iodide (DiR) and RNase‐free water 
(UltraPureTM DNase/RNase‐Free Distilled Water) were 
purchased from Life Technologies. D‐luciferin potassium 
salt was purchased from FUJIFILM Wako Pure Chemical 
Corporation. All other reagents were of analytical grade.
2.2 | Preparation of TS shRNA‐lipoplex 
(DFP‐10825)
Cationic liposome composed of DOPE:DOPC:DC‐6‐14 
(3:2:5 molar ratio) was prepared using a previously de-
scribed method.11 Thymidylate synthase shRNA and 
cationic liposome were mixed at a molar ratio of 1:2000 
(shRNA:lipid), and the mixture was vigorously vor-
texed for 10  minutes at room temperature to form a TS 
K E Y W O R D S
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shRNA/cationic liposome complex (TS shRNA‐lipoplex, 
DFP‐10825).
2.3 | Preparation of a peritoneally 
disseminated gastric cancer mouse model
MKN45 human gastric carcinoma was purchased from the 
RIKEN BioResource Center (RCB1001). NCI‐N87 human 
gastric carcinoma expressing firefly luciferase was purchased 
from Summit Pharmaceuticals International. The cells were 
cultured in RPMI‐1640 medium (FUJIFILM Wako Pure 
Chemical Corporation) supplemented with 10% of heat‐inac-
tivated fetal bovine serum (Corning), 100 units/mL penicil-
lin, and 100 μg/mL streptomycin (ICN Biomedicals) in a 5% 
CO2/air incubator at 37°C.
BALB/c nu/nu mice (male, 5 weeks old) were purchased 
from Japan SLC. The experimental animals were allowed 
free access to water and mouse chow and were housed under 
controlled environmental conditions (constant temperature 
and humidity, and a 12‐hour dark‐light cycle). All animal 
experiments were evaluated and approved by the Animal 
and Ethics Review Committee of Tokushima University. To 
prepare the peritoneal dissemination mouse model, either 
MKN45 cells or NCI‐N87 cells were intraperitoneally in-
jected into BALB/c nu/nu mice (5 × 106 cells/mouse). The 
development of a MKN45 peritoneally disseminated mouse 
model was confirmed by a >1.5 g decrease in body weight 
from Day 0 to Day 7 post‐tumor implantation. Development 
of the NCI‐N87 peritoneally disseminated mouse model was 
confirmed using an in vivo imaging system (IVIS; Xenogen) 
by intraperitoneal injection with 100 μL of 7.5 mg/mL D‐lu-
ciferin potassium salt followed by anesthesia administered 
by isoflurane inhalation. At 5 minutes post‐injection, biolu-
minescence of the disseminated tumors was observed with a 
CCD camera (exposure time was fixed at 30 seconds). The 
region of interest in bioluminescence was calculated and dis-
played as a photon count (photons/s).
2.4 | Survival and increased life span for 
a DFP‐10825‐treated MKN45 peritoneally 
disseminated mouse model
MKN45 peritoneally disseminated model mice were in-
traperitoneally injected with five injections of DFP‐10825 
(2.5, 5, 10, or 20  µg TS shRNA/mouse/d) twice weekly 
from Day 7 post‐inoculation of tumor cells. The antitumor 
effect was assessed in terms of both the mean survival time 
(MST [day]) and the increased life span (ILS [%]). The 
MST was identified with recording the mortality on a daily 
basis, and the ILS for the treatment groups was calculated 
using the following formula:
2.5 | Tumor growth inhibitory effect of 
DFP‐10825 in a peritoneally disseminated 
tumor model
Luciferase‐expressing peritoneally disseminated mouse 
models were prepared by intraperitoneal injection with ei-
ther luciferase‐expressing MKN45 cells or luciferase‐ex-
pressing NCI‐N87 cells. Peritoneally disseminated model 
mice were intraperitoneally injected with either DFP‐10825 
(20 µg/mouse/d, four or five injections once every 3 days, 
i.p.) or S‐1 (3.5 mg tegafur/kg/d, 14 doses every day, p.o.) 
from Day 7 post‐tumor implantation. The dose and the 
treatment schedule of S‐1 was adopted by reference to the 
paper from the other group.19 At selected time points, lu-
ciferase activity of the disseminated tumors was monitored 
with IVIS. In vivo imaging was performed as described 
above. The antitumor effect was assessed in terms of both 
the bioluminescent intensity (BLI) and the tumor growth 
inhibition (TGI [%]). The BLI was estimated based on the 
luciferase activity of peritoneally disseminated tumors, as 
determined by IVIS. The TGI was calculated using the fol-
lowing formula:
2.6 | Biodistribution of intraperitoneally 
injected DFP‐10825 in a peritoneally 
disseminated mouse model
To follow the biodistribution of TS shRNA and cationic li-
posomes, the DFP‐10825 formulation was labeled with either 
Alexa750‐labeled TS shRNA or hydrophobic DiR (a lipid 
membrane marker). Fluorescently labeled DFP‐10825 (20 µg 
TS shRNA/mouse) was intraperitoneally injected into a 
MKN45 peritoneally disseminated mouse model. At selected 
time points post‐injection (5, 10, and 30 minutes; 1, 3, 6, 12, 
24, 48, and 72 hours), the distribution of DFP‐10825 was vis-
ualized using IVIS. At a final time point, the mice were euth-
anized, and the tumor and organs including heart, lung, liver, 
spleen, and kidney were collected. Then, the accumulation of 
fluorescently labeled DFP‐10825 was observed using IVIS 
with a CCD camera (exposure time was fixed at 30 seconds) 
under the following filter setting: Ex 710 nm, Em 760 nm.
2.7 | Statistical analysis
Statistical differences between the groups were evalu-
ated by ANOVA with the Tukey post hoc test using the 
BellCurve for Excel software (Social Survey Research 
Information). All values are reported as the mean  ±  SD. 
The levels of significance were set at *P < .05, **P < .01 
vs. control, #P  <  .05 vs S‐1 treatment, and $$P  <  .01 vs 
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3 |  RESULTS
3.1 | Therapeutic effect of DFP‐10825 on 
the MKN45 peritoneally disseminated mouse 
model: dose dependency
To study the therapeutic effect of DFP‐10825 on peritoneally 
disseminated gastric cancer, different doses of DFP‐10825 
(2.5, 5.0, 10, or 20 µg TS shRNA/mouse/d) were intraperi-
toneally injected into a MKN45 peritoneally disseminated 
mouse model twice weekly. The intraperitoneal injection of 
DFP‐10825 prolonged the survival times of the mice, com-
pared with the untreated control mice (Figure 1A). The MST 
and ILS were increased in a dose‐dependent manner (Table 
1). The body weight of the treated mice gradually decreased 
with each dose of DFP‐10825, and yet, it was comparable to 
that of the untreated control mice (Figure 1B). These results 
indicate that intraperitoneally injected DFP‐10825 exerts po-
tent therapeutic efficacy on peritoneally disseminated gastric 
cancer without the severe adverse effects.
3.2 | DFP‐10825 suppression of tumor 
growth in the MKN45 peritoneally 
disseminated mouse model
The suppressive effect that DFP‐10825 exerted on tumor 
growth was compared with that of conventional standard 
chemotherapy for gastric cancer, S‐1. The growth of implanted 
tumor cells in the peritoneal cavity was monitored with IVIS 
by tracing the luciferase activity of the tumor cells (Figure 
2A). Regardless of the treatment group, intraperitoneal lucif-
erase activity regarding tumor growth was detected in all mice. 
In the untreated control group, the luciferase activity increased 
with increasing time following implantation (Figure 2A,B). In 
the S‐1‐treated mice, the luciferase activity also increased with 
an increase in time and the luciferase activity at each time point 
was almost the same as that for the control mice (Figure 2A,B). 
This observation indicates that S‐1 showed no tumor growth 
inhibition under our current experimental conditions. On the 
other hand, in DFP‐10825‐treated mice, the intraperitoneal lu-
ciferase activity increased slowly, and at each time point, with 
the exception of the earliest point, the luciferase activity was 
smaller than that for either the S‐1‐treated or the control mice 
(Figure 2A,B). Body weights of the mice treated with both S‐1 
and DFP‐10825 gradually decreased, but were comparable to 
that of the untreated control mice (Figure 2C). These results 
indicate that intraperitoneally injected DFP‐10825 showed 
TGI without severe adverse effects, which is consistent with 
the finding shown in Figure 1.
3.3 | Tumor growth suppressive effect of 
DFP‐10825 on a NCI‐N87‐LUC peritoneally 
disseminated mouse model
To further confirm the tumor growth suppression effect 
of DFP‐10825, we next prepared a peritoneally dissemi-
nated gastric cancer model with another cell line, NCI‐N87 
human gastric carcinoma. NCI‐N87 cells gradually develop 
in the peritoneum after intraperitoneal implantation and in-
duce the accumulation of tumoral ascites fluid in the peri-
toneal cavity,20 which is highly consistent with the clinical 
conditions of peritoneal dissemination. Either DFP‐10825 
(20 µg/mouse/d, five injections once every 3 days, i.p.) or 
S‐1 (3.5 mg tegafur/kg/d, 14 doses once every day, p.o.) 
was administered into the model mice. Peritoneal luciferase 
activity was detected in all mice when the treatments were 
begun (Figure 3A), indicating that the NCI‐N87 peritone-
ally disseminated tumors had begun to grow in the perito-
neum. In the untreated control mice, peritoneal luciferase 
activity gradually increased with time. In the S‐1‐treated 
mice, the peritoneal luciferase activity was maintained at a 
constant level during the treatment period (Day 7‐Day 21) 
and then began to increase to a controlled level. The TGI 
F I G U R E  1  Therapeutic effect of DFP‐10825 on a MKN45 peritoneally disseminated mouse model. MKN45 peritoneally disseminated 
model mice were intraperitoneally injected with five injections of DFP‐10825 (2.5, 5, 10, or 20 µg thymidylate synthase [TS] short hairpin RNA 
[shRNA]/mouse/d) twice weekly from Day 7 post‐tumor implantation. A, Survival periods for the mice were monitored daily (n = 9‐10). B, Body 
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value for the S‐1 treatment group was 44.7%. This indicates 
that S‐1 treatment suppressed the tumor growth in this gas-
tric cancer disseminated model. In the DFP‐10825‐treated 
mice, the luciferase activity was somewhat decreased dur-
ing the treatment period (Day 7‐Day 21) and then began 
to increase. For the DFP‐10825‐treated mice, however, the 
luciferase activity at Day 45 was much smaller than that of 
both the untreated mice and the S‐1‐treated mice. The TGI 
value for DFP‐10825 was 96%. All mice in both treatment 
groups showed a comparable body weight increase (Figure 
3B). These results indicate that the intraperitoneal injection 
of DFP‐10825 showed a superior tumor growth suppres-
sive effect without severe side effects in yet another gastric 
cancer peritoneally disseminated mouse model.
3.4 | Biodistribution of intraperitoneally 
injected DFP‐10825 in a MKN45 peritoneally 
disseminated mouse model
To track the biodistribution of DFP‐10825 following in-
traperitoneal injection, two types of fluorescently labeled 
T A B L E  1  MST and ILS of treated a MKN45 peritoneally 
disseminated mouse model from the data of Figure 1A
Treatment Doses MST (d) ILS (%)
Control — 48.9 ± 3.5 —
DFP‐10825 2.5 µg TS shRNA 49.3 ± 3.9 0.8
5.0 µg TS shRNA 52.8 ± 3.6 8.0
10 µg TS shRNA 53.6 ± 3.9 9.6
20 µg TS shRNA 56.6 ± 4.2**,$$ 15.7
Note: MST (d) and ILS (%) were determined from the data shown in Figure 1A. 
The MSTs are represented as the mean ± SD (n = 9‐10, **P < .01 vs control, 
$$P < .01 vs 2.5 µg TS shRNA). The ILSs were calculated using a formula 
described in Section 2.
Abbreviations: ILS, increased life span; MST, mean survival time; TS, thymi-
dylate synthase.
F I G U R E  2  Tumor growth suppressive effect of DFP‐10825 in a MKN45 peritoneally disseminated mouse model. Luciferase‐expressing 
MKN45 peritoneally disseminated model mice were injected with either DFP‐10825 (20 µg/mouse/d, four doses once every 3 d, i.p.) or S‐1 (3.5 mg 
tegafur/kg/d, 14 doses once every day, p.o.) from Day 7 post‐tumor implantation. A, Bioluminescence of the disseminated tumors was monitored 
with in vivo imaging system at selected time points (Days 7, 14, 18, and 21 post‐tumor implantation). Two of 10 mice in the DFP‐10825‐treated 
group died accidently due to excessive anesthesia. B, Bioluminescent intensities of the disseminated tumors were calculated from the images in 
Figure 2A. The data are represented as the mean ± SD (n = 10, *P < .05, **P < .01 vs control, #P < .05 vs S‐1). C, Body weight changes of the 
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DFP‐10825 were prepared; one formulation contained 
Alexa750‐labeled TS shRNA and the other contained a 
hydrophobic DiR‐labeled liposomal membrane. These 
fluorescently labeled DFP‐10825 samples were intraperi-
toneally injected into different MKN45 peritoneally dis-
seminated model mice, and the in vivo distributions were 
visualized using IVIS (Figure 4A). Free Alexa750‐labeled 
TS shRNA was retained within the peritoneal cavity at ear-
lier time points, then distributed over the body, and rap-
idly eliminated from the body at 6  hours post‐injection. 
DFP‐10825 containing either Alexa750‐labeled TS shRNA 
or DiR was retained in the peritoneal cavity without distri-
bution over the body at 72 hours post‐injection. At 72 hours 
post‐injection, the tumors and the normal organs, includ-
ing heart, lung, liver, spleen, and kidney, were harvested, 
and the accumulation of DFP‐10825 in these tissues was 
observed (Figure 4B). Free Alexa750‐labeled TS shRNA 
showed no accumulation in any tissues. Interestingly, 
DFP‐10825 containing either Alexa750‐labeled TS shRNA 
or DiR was selectively accumulated in the peritoneally 
disseminated tumor masses without accumulation in any 
abdominal organs. These results indicate that intraperito-
neally injected DFP‐10825 was retained in the peritoneal 
cavity for extended periods of time and was selectively ac-
cumulated in the peritoneally disseminated tumors, which 
efficiently delivered TS shRNA to the disseminated tumors 
and resulted in TS shRNA‐mediated RNAi.
4 |  DISCUSSION
Peritoneal dissemination is frequently detected in patients 
with advanced gastrointestinal cancer,21,22 which causes a 
poor prognosis for the patient. A novel therapeutic approach 
to controlling peritoneal dissemination in advanced gastric 
cancer is urgently needed, because it would increase both the 
quality of life and the survival of patients. Thus far, how-
ever, neither systemic chemotherapy nor intraperitoneal 
chemotherapy has shown promising clinical benefits.6,23,24 In 
the current study, we showed that intraperitoneal injection 
of DFP‐10825 induced desired tumor growth suppression 
in two different types of peritoneally disseminated gastric 
cancer models (MKN45 and NCI‐N87) (Figures 2A,B and 
3A) and increased the survival time of a MKN45 peritone-
ally disseminated gastric cancer model (Figure 1A) without 
severe side effects (Figures 1B, 2C and 3B). Our DFP‐10825 
model could become an alternative approach for improving 
the outcome of patients with peritoneally disseminated gas-
tric cancer.
Thymidylate synthase has been recognized as a rate‐
limiting enzyme in de novo pyrimidine biosynthesis and 
plays a key role in the metabolism of folate and deoxy-
thymidine for DNA synthesis and repair.25,26 Several stud-
ies reported that the TS‐expression level is related to the 
therapeutic performance in clinical cases for the treatment 
of gastric cancer; the higher the TS expression, the poorer 
the therapeutic performance.27,28 Hence, TS is considered 
a critical target for the treatment of malignantly advanced 
gastric cancer. The Japanese guidelines on gastric can-
cer treatment (updated in 2014)29 list S‐1 plus cisplatin 
(CDDP) as the first‐line chemotherapy for advanced gastric 
cancer. It is well‐known that TS is a target enzyme of 5‐FU 
derived from S‐1. DFP‐10825 is an RNAi therapeutic com-
posed of TS shRNA conjugated with cationic liposomes 
that has downregulated TS in cancer xenograft models.11,30 
Accordingly, DFP‐10825 should be a feasible approach to 
control the malignancy of metastatic advanced gastric can-
cer and would meet the Japanese Gastric Cancer Treatment 
Guidelines.
As shown in Figure 4A, intraperitoneally injected 
DFP‐10825 demonstrated prolonged retention in the peri-
toneal cavity compared with a free TS shRNA formulation 
F I G U R E  3  Tumor growth suppressive effect of DFP‐10825 in a NCI‐N87 peritoneally disseminated mouse model. Luciferase‐expressing 
NCI‐N87 peritoneally disseminated model mice were injected with either DFP‐10825 (20 µg/mouse/d, five injections once every 3 d, i.p.) or S‐1 
(3.5 mg tegafur/kg/d, 14 doses once every day, p.o.) from Day 7 post‐tumor implantation. A, Bioluminescent intensities of the disseminated tumors 
were calculated from the data imaged using in vivo imaging system at selected time points (Days 7, 23, 30, 37, and 45 post‐tumor implantation). 
The data are represented as the mean ± SD (n = 2‐3, *P < .05, **P < .01 vs control). B, Body weight change of the mice was monitored at selected 
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(Figure 4A). Such a long retention of DFP‐10825 in the 
body cavity was also observed following intrathecal in-
jection into a malignant pleural mesothelioma xenograft 
model.11 In addition, interestingly, a current study showed 
a selective accumulation of DFP‐10825 in peritoneally dis-
seminated tumors (Figure 4B), although the mechanism 
behind such selective tumor accumulation remains unclear. 
Figure 4 demonstrates that the distribution of fluorescent‐
labeled TS shRNA was highly consistent with that of cat-
ionic liposomes containing DiR, which indicates that TS 
shRNA was stably complexed with cationic liposomes even 
in the peritoneal cavity and was delivered by the cationic 
liposomes into the peritoneally disseminated tumor tissue. 
To cause a gene‐silencing effect, shRNA should be deliv-
ered to target cells in a complex formulation with a deliv-
ery carrier, because naked shRNA is easily degraded by the 
exposure of ribonuclease, and it does not easily penetrate 
the plasma membrane of target cells.31-33 Our cationic lipo-
some, composed of DFP‐10825, could be a feasible viable 
system for the delivery of shRNA/siRNA to peritoneally 
disseminated tumors.
In the present study, the intraperitoneal injection of 
DFP‐10825 did not cause significant body weight changes 
compared with an untreated control (Figures 1B, 2C and 3B). 
Several RNAi drug candidates are known to induce strong sys-
temic adverse effects as a result of inducing a cytokine storm, 
which is caused via stimulation of a Toll‐like receptor family 
that is sensed by nucleic acid molecules.34,35 The induction of 
such innate immune responses is known as a bottleneck in the 
clinical development of RNAi drugs. Meanwhile, to avoid such 
an intrinsic issue, the siRNA of Patisiran (ONPATTRO®), the 
first approved therapeutic form of RNAi36 that was originally 
formulated in lipid nanoparticles,37-39 is directly conjugated 
with an N‐acetylgalactosamine in this formulation, which can 
facilitate the delivery of RNAi molecules to hepatocytes.40 
DFP‐10825, an RNAi formulation for local administration, 
avoids such systemic adverse events, because very little of the 
TS shRNA in the DFP‐10825 formulation escapes into blood 
circulation from the peritoneal cavity after intraperitoneal in-
jection (Figure 4A), and as a result, the formulation does not 
accumulate in immune organs such as the spleen (Figure 4B). 
These results indicate that DFP‐10825 for local injection is a 
safer RNAi formulation than other RNAi formulations.
We recently reported that DFP‐10825 also induced tumor 
growth suppression in a malignant pleural mesothelioma 
xenograft model11 and in a peritoneal disseminated ovarian 
cancer xenograft model.30 In the current study, DFP‐10825 
also showed a superior suppressive effect on tumor growth 
in a peritoneally disseminated gastric cancer xenograft 
model (Figures 1-3). Malignant pleural mesothelioma is a 
cancer that develops in the pleural cavities. The life expec-
tancy of patients with pleural mesothelioma is often less than 
15 months.41,42 Peritoneal dissemination is frequently caused 
by recurrent abdominal malignancy in patients with gastro-
intestinal cancer,21,22 ovarian cancer,43-45 or pancreatic can-
cer,46-48 resulting in a poor prognosis for patients. With a great 
deal of continuous effort to improve the chemotherapeutic 
regimens, the prognosis of these advanced cancers has cur-
rently improved.49,50 However, alternative approaches to fur-
ther improve the prognosis are urgently needed. DFP‐10825 
is an RNAi formulation for local administration that is ca-
pable of inducing tumor growth suppression by delivering 
RNAi molecules to target tumor cells such as the pleural 
mesothelioma cells and peritoneal disseminated cells that 
exist in thoracic or abdominal cavities. DFP‐10825 might be 
a reliable alternative to the traditional chemotherapeutic regi-
men via suppression of tumor growth without severe adverse 
effects, which should achieve a higher therapeutic index.
F I G U R E  4  Biodistribution of intraperitoneally injected DFP‐10825 in a MKN45 peritoneally disseminated mouse model. MKN45 
peritoneally disseminated model mice were intraperitoneally injected with free Alexa750‐labeled TS short hairpin RNA (shRNA), DFP‐10825 
containing Alexa750‐labeled TS shRNA, or DFP‐10825 containing 1,1′‐dioctadecyl‐3,3,3′,3′‐tetramethylindotricarbocyanine iodide (DiR) (20 µg 
thymidylate synthase [TS] shRNA/mouse). A, The fluorescence of Alexa750‐labeled TS shRNA or DiR in the formulation was monitored with 
in vivo imaging system (IVIS) at selected time points (5, 10, and 30 min; 1, 3, 6, 12, 24, 48, and 72 h post‐injection). B, After preserving an 
image at 72 h post‐injection, tumors (Tu) and organs including heart (He), lung (Lu), liver (Li), spleen (Sp), and kidney (Ki) were harvested. The 
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5 |  CONCLUSIONS
Herein, we provide the first description of intraperito-
neally injected DFP‐10825, a conjugate of TS shRNA with 
cationic liposomes, which produced a dose‐dependent 
therapeutic effect on a peritoneally disseminated gastric 
cancer model. The growth inhibitory effect of DFP‐10825 
on peritoneally disseminated tumors was superior to a 
conventional S‐1 treatment. Importantly, treatment with 
DFP‐10825 showed no systemic adverse effects. These re-
sults strongly indicate that intraperitoneal treatment with 
DFP‐10825 would provide a new therapeutic approach that 
could improve the outcomes for patients with advanced 
gastric cancer.
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